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Abstract
The Juvenile Arthritis Multidimensional Assessment Report (JAMAR) is a new parent/patient reported outcome measure 
that enables a thorough assessment of the disease status in children with juvenile idiopathic arthritis (JIA). We report the 
results of the cross-cultural adaptation and validation of the parent and patient versions of the JAMAR in the Omani Arabic 
language. The reading comprehension of the questionnaire was tested in 10 JIA parents and patients. Each participating 
centre was asked to collect demographic, clinical data and the JAMAR in 100 consecutive JIA patients or all consecutive 
patients seen in a 6-month period and to administer the JAMAR to 100 healthy children and their parents. The statistical 
validation phase explored descriptive statistics and the psychometric issues of the JAMAR: the 3 Likert assumptions, floor/
ceiling effects, internal consistency, Cronbach’s alpha, interscale correlations, test–retest reliability, and construct validity 
(convergent and discriminant validity). A total of 57 JIA patients (22.8% systemic, 28.1% oligoarticular, 35.1% RF negative 
polyarthritis, 14.0% other categories) and 85 healthy children, were enrolled in two centres. Notably, none of the enrolled 
JIA patients is affected with enthesitis-related arthritis or undifferentiated arthritis. The JAMAR components discriminated 
well healthy subjects from JIA patients. All JAMAR components revealed satisfactory psychometric performances. In con-
clusion, the Omani Arabic version of the JAMAR is a valid tool for the assessment of children with JIA and is suitable for 
use both in routine clinical practice and clinical research.
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Introduction
The aim of the present study was to cross-culturally adapt 
and validate the Omani Arabic parent, child/adult version of 
the Juvenile Arthritis Multidimensional Assessment Report 
(JAMAR) [1] in patients with juvenile idiopathic arthritis 
(JIA). The JAMAR assesses the most relevant parent/patient 
reported outcomes in JIA, including overall well-being, 
functional status, health related quality of life (HRQoL), 
pain, morning stiffness, disease activity/status/course, 
articular and extra-articular involvement, drug-related side 
effects/compliance and satisfaction with illness outcome.
This project was part of a larger multinational study con-
ducted by the Paediatric Rheumatology International Trials 
Organisation (PRINTO) [2] aimed to evaluate the Epide-
miology, Outcome and Treatment of Childhood Arthritis 
(EPOCA) in different geographic areas [3].
We report herein the results of the cross-cultural adapta-
tion and validation of the parent and patient versions of the 
JAMAR in the Omani Arabic language.
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Materials and methods
The methodology employed has been described in detail in 
the introductory paper of the supplement [4]. In brief, it was 
a cross-sectional study of JIA children, classified according 
to the ILAR criteria [5, 6] and enrolled from January 2012 to 
April 2013. Children were recruited after Ethics Committee 
approval and consent from at least one parent.
The JAMAR
The JAMAR [1] includes the following 15 sections:
 1. Assessment of physical function (PF) using 15-items 
in which the ability of the child to perform each task 
is scored as follows: 0 = without difficulty, 1 = with 
some difficulty, 2 = with much difficulty, 3 = unable to 
do and not applicable if it was not possible to answer 
the question or the patient was unable to perform the 
task due to their young age or to reasons other than 
JIA. The total PF score ranges from 0 to 45 and has 3 
components: PF-lower limbs (PF -LL); PF-hand and 
wrist (PF -HW) and PF-upper segment (PF-US) each 
scoring from 0 to 15 [7]. Higher scores indicating 
higher degree of disability [8–10];
 2. Rating of the intensity of the patient’s pain on a 
21-numbered circle visual analogue scale (VAS) [11];
 3. Assessment of the presence of joint pain or swelling 
(present/absent for each joint);
 4. Assessment of morning stiffness (present/absent);
 5. Assessment of extra-articular symptoms (fever and 
rash) (present/absent);
 6. Rating of the level of disease activity on a 21-circle 
VAS;
 7. Rating of disease status at the time of the visit (cat-
egorical scale);
 8. Rating of disease course from previous visit (categori-
cal scale);
 9. Checklist of the medications the patient is taking (list 
of choices);
 10. Checklist of side effects of medications;
 11. Report of difficulties with medication administration 
(list of items);
 12. Report of school/university/work problems caused by 
the disease (list of items);
 13. Assessment of HRQoL, through the Physical Health 
(PhH), and Psychosocial Health (PsH) subscales (5 
items each) and a total score. The four-point Likert 
response, referring to the prior month, are ‘never’ 
(score=0), ‘sometimes’ (score=1), ‘most of the time’ 
(score=2) and ‘all the time’ (score=3). A ‘not assess-
able’ column was included in the parent version of the 
questionnaire to designate questions that cannot be 
answered because of developmental immaturity. The 
total HRQoL score ranges from 0 to 30, with higher 
scores indicating worse HRQoL. A separate score for 
PhH and PsH (range 0-15) can be calculated (12–14);
 14. Rating of the patient’s overall well-being on a 21-num-
bered circle VAS;
 15.  A question about satisfaction with the outcome of the 
illness (Yes/No) [15]
The JAMAR is available in three versions, one for parent 
proxy-report (child’s age 2–18), one for child self-report, 
with the suggested age range of 7–18 years, and one for 
adults.
Cross‑cultural adaptation and validation
The process of cross-cultural adaptation was conducted 
according to international guidelines with 2–3 forward and 
backward translations. In those countries for which the trans-
lation of JAMAR had been already cross-cultural adapted 
in a similar language (i.e. Spanish in South American coun-
tries), only the probe technique was performed. Reading 
comprehension and understanding of the translated ques-
tionnaires were tested in a probe sample of 10 JIA parents 
and 10 patients.
Each participating centre was asked to collect demo-
graphic, clinical data and the JAMAR in 100 consecutive 
JIA patients or all consecutive patients seen in a 6-month 
period and to administer the JAMAR to 100 healthy chil-
dren and their parents.
The statistical validation phase explored the descrip-
tive statistics and the psychometric issues [16]. In par-
ticular, we evaluated the following validity components: 
the first Likert assumption [mean and standard devia-
tion (SD) equivalence]; the second Likert assumption or 
equal item–scale correlations (Pearson r: all items within 
a scale should contribute equally to the total score); third 
Likert assumption (item internal consistency or linear-
ity for which each item of a scale should be linearly 
related to the total score that is 90% of the items should 
have Pearson r ≥ 0.4); floor/ceiling effects (frequency of 
items at lower and higher extremes of the scales, respec-
tively); internal consistency, measured by the Cronbach’s 
alpha, interscale correlation (the correlation between two 
scales should be lower than their reliability coefficients, 
as measured by Cronbach’s alpha); test–retest reliability 
or intra-class correlation coefficient (reproducibility of 
the JAMAR repeated after 1 or 2 weeks); and construct 
validity in its two components: the convergent or external 
validity which examines the correlation of the JAMAR 
sub-scales with the 6 JIA core set of variables, with the 
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addition of the parent assessment of disease activity and 
pain by the Spearman’s correlation coefficients (r) [17] 
and the discriminant validity, which assesses whether the 
JAMAR discriminates between the different JIA catego-
ries and healthy children [18].
Quantitative data were reported as medians with 1st 
and 3rd quartiles and categorical data as absolute frequen-
cies and percentages.
The complete Omani Arabic parent and patient ver-
sions of the JAMAR are available upon request to 
PRINTO.
Results
Cross‑cultural adaptation
The Omani Arabic JAMAR was fully cross-culturally 
adapted from the Arabic version performed by the 
PRINTO centre in Saudi Arabia with no forward and 
backward translation.
All 123 lines of the parent version of the JAMAR 
were understood by at least 80% of the 10 parents tested 
(median = 100%; range: 100–100%). All the 120 lines 
of the patient version of the JAMAR were understood 
by at least 80% of the children (median = 100%; range: 
100–100%). Both versions of the JAMAR were unmodi-
fied after the probe technique.
Demographic and clinical characteristics 
of the subjects
A total of 58 JIA patients and 85 healthy children (total of 
143 subjects), were enrolled at two paediatric rheumatology 
centres. One patient did not give the consent to use his/her 
data.
In the 57/142 (40.1%) JIA subjects, the JIA categories 
were 22.8% with systemic arthritis, 28.1% with oligoar-
thritis, 35.1% with RF negative polyarthritis, 10.5% with 
RF positive polyarthritis and 3.5% with psoriatic arthri-
tis. Notably, none of the enrolled JIA patients is affected 
with enthesitis-related arthritis or undifferentiated arthritis 
(Table 1).
All the 142 enrolled subjects had the parent version of 
the JAMAR completed by a parent (57 from parents of 
JIA patients and 85 from parents of healthy children). The 
JAMAR was completed by 108/142 (76.1%) mothers and 
34/142 (23.9%) fathers. The child version of the JAMAR 
was completed by 120/142 (84.5%) children aged 7.1 or 
older.
Discriminant validity
The JAMAR results are presented in Table 1, including 
the scores [median (1st–3rd quartile)] obtained for the PF, 
the PhH, the PsH subscales and total score of the HRQoL 
scales. The JAMAR components discriminated well between 
healthy subjects and JIA patients.
In summary, the JAMAR revealed that JIA patients had 
a greater level of disability and pain, as well as a lower 
HRQoL than their healthy peers.
Psychometric issues
The main psychometric properties of both parent and child 
versions of the JAMAR are reported in Table 2. The follow-
ing "Results" section refers mainly to the parent’s version 
findings, unless otherwise specified.
Descriptive statistics (first Likert assumption)
There were no missing results for all JAMAR items, since 
data were collected through a web-based system that did not 
allow to skip answers and input of null values. The response 
pattern for both PF and HRQoL was positively skewed 
toward normal functional ability and normal HRQoL. A 
reduced number of response choices were used for the dif-
ferent HRQoL items except for item 1, whereas a reduced 
number of response choices were used for all the PF items.
The mean and SD of the items within a scale were 
roughly equivalent for the PF and for the HRQoL items (data 
not shown). The median number of items marked as not 
applicable was 1% (0–2.0%) for the PF and 6.0% (3–7.0%) 
for the HRQoL.
Floor and ceiling effect
The median floor effect was 89.5% (78.9–94.7%) for the 
PF items, 66.7% (59.6–66.7%) for the HRQoL PhH items, 
and 80.7% (73.7–89.5%) for the HRQoL PsH items. The 
median ceiling effect was 0.0% (0.0–0.0%) for the PF 
items, 0.0% (0.0–0.0%) for the HRQoL PhH items, and 
0.0% (0.0–0.0%) for the HRQoL PsH items. The median 
floor effect was 40.4% for the pain VAS, 36.8% for the 
disease activity VAS and 40.4% for the well-being VAS. 
The median ceiling effect was 0.0% for the pain VAS, 
0.0% for the disease activity VAS and 0.0% for the well-
being VAS.
Equal item–scale correlations (second Likert 
assumption)
Pearson item–scale correlations corrected for overlap were 
roughly equivalent for items within a scale for 87% of the PF 
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Table 1  Descriptive statistics (medians, 1st–3rd quartiles or absolute frequencies and %) for the 57 JIA patients
Data related to the JAMAR refers to the 57 JIA patients and to the 85 healthy subjects for whom the questionnaire has been completed by the 
parents
JAMAR Juvenile Arthritis Multidimensional Assessment Report, ESR erythrocyte sedimentation rate, MD medical doctor, VAS visual analogue 
scale (score 0–10; 0 = no activity, 10 = maximum activity), LOM limitation of motion, ANA anti-nuclear antibodies, PF physical function (total 
score ranges from 0 to 45), HRQoL health related quality of life (total score ranges from 0 to 30), PhH physical health (total score ranges from 0 
to 15), PsH psychosocial health (total score ranges from 0 to 15)
p values refers to the comparison of the different JIA categories or to JIA versus healthy. *p < 0.05, **p < 0.001, #p < 0.0001
Systemic Oligoarthritis RF-poly-arthritis RF + Poly-arthritis Psoriatic arthritis All JIA patients Healthy
N = 13 N = 16 N = 20 N = 6 N = 2 N = 57 N = 85
Female 6 (46.2%) 10 (62.5%) 17 (85%) 6 (100%) 1 (50%) 40 (70.2%)* 42 (49.4%)*
Age at visit 10.2 (6.4–12.7) 5.1 (2.6–9.1) 11.4 (8.8–12.4) 9.5 (8.2–13.6) 14.9 (14.6–15.3) 9.8 (5.4–12.3)* 10.7 (9.3–12.3)
Age at onset 5.9 (3.5–8.2) 2.2 (1.7–3.2) 8.6 (6–10.5) 6.9 (4.2–8.8) 10 (8.8–11.1) 5.9 (2.4–9.1)**
Disease duration 3.1 (0.9–6.1) 0.8 (0.2–4.2) 2.3 (1.2–4.9) 3.8 (0.8–4.9) 5 (3.4–6.5) 2.8 (0.8–4.9)
ESR 18 (8–28) 10.5 (5–22) 17 (6–27) 11 (7–17) 10 (6–14) 14 (6–24)
MD VAS 
(0–10 cm)
0.5 (0–1) 0.5 (0.3-2) 0.5 (0-2.5) 1.8 (1.5–2.5) 0.5 (0.5–0.5) 0.5 (0–2)
No. of swollen 
joints
0 (0–1) 1 (0–1) 0 (0–0) 1 (0–1) 0 (0–0) 0 (0–1)
No. of joints with 
pain
0 (0–0) 0 (0–0.5) 0 (0–1.5) 0.5 (0–2) 0 (0–0) 0 (0–1)
No. of joints with 
LOM
0 (0–0) 0 (0–0) 0 (0–0.5) 0 (0–1) 0 (0–0) 0 (0–0)
No. of active 
joints
0 (0–1) 1 (0–1) 0 (0–1) 1 (0–1) 0 (0–0) 0 (0–1)
Active systemic 
features
2 (15.4%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 2 (3.5%)
ANA status 0 (0%) 1 (6.3%) 2 (10%) 1 (16.7%) 0 (0%) 4 (7%)
Uveitis 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%) 0 (0%)
PF Total Score 0 (0–1) 1.5 (0-6.5) 0.5 (0–3) 1 (0–2) 0 (0–0) 0 (0–3) 0 (0–0)#
Pain VAS 0 (0–1) 1.8 (0.5–3.3) 0.3 (0–2) 0.8 (0–1) 1.3 (1–1.5) 0.5 (0–2) 0 (0–0)#
Disease Activity 
VAS
0 (0–1) 1.5 (0.5–2.5) 0.5 (0–2.5) 1.5 (0–2) 0.8 (0.5–1) 1 (0–2)
Well-being VAS 0 (0–0) 1.5 (0.3–2.8) 0.5 (0–2.5) 1.8 (0–2) 0.5 (0.5–0.5) 0.5 (0–2)
HRQoL PhH 0 (0–1) 2 (0–99) 1 (0–4.5) 0.5 (0–3) 1.5 (0–3) 1 (0–4) 0 (0–0)#
HRQoL PsH 0 (0–1) 1.5 (0–99) 0 (0–0) 0 (0–1) 1 (0–2) 0 (0–1) 0 (0–0)#
HRQoL Total 
Score
0 (0–1) 8.5 (1–99) 2 (0–5) 1 (0–3) 2.5 (0–5) 1 (0–6) 0 (0–0) #
Pain/swell. in > 1 
joint
4 (30.8%) 11 (68.8%) 10 (50%) 3 (50%) 1 (50%) 29 (50.9%) 0 (0%)#
Morning stiff-
ness > 15 min
0 (0%) 3 (18.8%) 1 (5%) 1 (16.7%) 0 (0%) 5 (8.8%) 0 (0%)*
Subjective remis-
sion
4 (30.8%) 12 (75%) 8 (40%) 3 (50%) 1 (50%) 28 (49.1%)
In treatment 11 (84.6%) 13 (81.3%) 15 (75%) 6 (100%) 2 (100%) 47 (82.5%)
Reporting side 
effects
3/11 (27.3%) 3/13 (23.1%) 4/15 (26.7%) 2/6 (33.3%) 0 (0%) 12/47 (25.5%)
Taking medication 
regularly
10/11 (90.9%) 13/13 (100%) 15/15 (100%) 6 (100%) 2 (100%) 46/47 (97.9%)
With problems 
attending school
2/9 (22.2%) 1/7 (14.3%) 0 (0%) 0 (0%) 0 (0%) 3/37 (8.1%) 0 (0%)*
Satisfied with dis-
ease outcome
7 (53.8%) 7 (43.8%) 7 (35%) 2 (33.3%) 1 (50%) 24 (42.1%)
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items, with the exception of PF items 8 and 13, and for 70% 
of the HRQoL items, with the exception of items 1, 5 and 6.
Items internal consistency (third Likert assumption)
Pearson item–scale correlations were ≥ 0.4 for 60% of items 
of the PF (except for PF items 4, 5, 6, 9, 11 and 15) and 80% 
of items of the HRQoL (except for HRQoL items 8 and 9).
Cronbach’s alpha internal consistency
Cronbach’s alpha was 0.72 for PF-LL, 0.72 for PF-HW, 0.72 
for PF-US. Cronbach’s alpha was 0.86 for HRQoL-PhH and 
0.73 for HRQoL-PsH.
Table 2  Main psychometric characteristics between the parent and child version of the JAMAR
JAMAR Juvenile Arthritis Multidimensional Assessment Report, JIA juvenile idiopathic arthritis, VAS visual analogue scale, PF physical func-
tion, HRQoL health related quality of life, PhH physical health, PsH psychosocial health, PF-LL PF-lower limbs, PF-HW PF-hand and wrist, 
PF-US PF-upper segment
Parent, N = 57/142 Child, N = 36/120
Missing values (1st–3rd quartiles) No missing values No missing values
Response pattern PF and HRQoL positively skewed PF and HRQoL positively skewed
Floor effect, median
 PF 89.5% 83.3%
 HRQoL PhH 66.7% 75.0%
 HRQoL PsH 80.7% 94.4%
 Pain VAS 40.4% 41.7%
 Disease activity VAS 36.8% 47.2%
 Well-being VAS 40.4% 41.7%
Ceiling effect, median
 PF 0.0% 8.3%
 HRQoL PhH 0.0% 0.0%
 HRQoL PsH 0.0% 0.0%
 Pain VAS 0.0% 0.0%
 Disease activity VAS 0.0% 0.0%
 Well-being VAS 0.0% 0.0%
 Items with equivalent item–scale correlation 87% for PF, 70% for HRQoL 100% for PF, 87% for HRQoL
 Items with item–scale correlation ≥ 0.4 60% for PF, 80% for HRQoL 100% for PF, 60% for HRQoL
Cronbach’s alpha
 PF-LL 0.72 0.92
 PF-HW 0.72 0.94
 PF-US 0.72 0.95
 HRQoL-PhH 0.86 0.76
 HRQoL-PsH 0.73 0.61
Items with item–scale correlation lower than the Cronbach alpha 87% for PF, 90% for HRQoL 93% for PF, 80% for HRQoL
Test–retest intraclass correlation
 PF total score 0.96 0.91
 HRQoL-PhH 0.00 0.00
 HRQoL-PsH 1.00 0.00
Spearman correlation with JIA core-set variables, median
 PF 0.6 0.5
 HRQoL PhH 0.4 0.5
 HRQoL PsH 0.2 0.2
 Pain VAS 0.4 0.5
 Disease activity VAS 0.5 0.5
 Well-being VAS 0.5 0.6
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Interscale correlation
The Pearson correlation of each item of the PF and the 
HRQoL with all items included in the remaining scales 
of the questionnaires was lower than the Cronbach’s alpha 
(except for PF items 8 and 13 and for the HRQoL item 6).
Test–retest reliability
Reliability was assessed in 10 JIA patients, by re-adminis-
tering both versions (parent and child) of the JAMAR after a 
median of 7 days (7–7 days). The intraclass correlation coef-
ficients (ICC) for the PF total score showed an almost per-
fect reproducibility (ICC = 0.96). The ICC for the HRQoL 
PhH showed a poor reproducibility (ICC = 0.0), whereas for 
the HRQoL PsH showed an almost perfect reproducibility 
(ICC = 1.0).
Convergent validity
The Spearman correlation of the PF total score with the 
JIA core set of outcome variables ranged from 0.3 to 0.7 
(median = 0.6). The PF total score best correlation was 
observed with the parent global assessment of well-being 
(r = 0.8, p < 0.001). The correlation of the PF total score 
with the ESR was not significant (p = 0.65). For the HRQoL, 
the median correlation of the PhH with the JIA core set of 
outcome variables ranged from 0.2 to 0.7 (median = 0.4), 
whereas for the PsH ranged from 0.1 to 0.4 (median = 0.2). 
The PhH showed the best correlation with the parent global 
assessment of well-being (r = 0.8, p < 0.001) and the PsH 
with the parent’s assessment of pain (r = 0.4, p = 0.002). 
The median correlations between the pain VAS, the well-
being VAS, and the disease activity VAS and the physician-
centered and laboratory measures were 0.4 (0.2–0.6), 0.5 
(0.2–0.6), 0.5 (0.2–0.6), respectively.
Discussion
In this study, the Omani Arabic version of the JAMAR is the 
result of the local adaptation of the translation in Arabic per-
formed by the PRINTO centre in Saudi Arabia. According to 
the results of the validation analysis, the Omani Arabic par-
ent and patient versions of the JAMAR possess satisfactory 
psychometric properties. The disease-specific components 
of the questionnaire discriminated well between patients 
with JIA and healthy controls.
Psychometric performances were good for all domains 
of the JAMAR with some exceptions: 6 PF items (“squat”, 
“bend down to pick up an object off the floor”, “carry out 
activities that require the use of fingers”, “open a door by 
lowering the handle”, “stretch out arms” and “bite a sand-
wich or an apple”) and 2 HRQoL items (“have trouble get-
ting along with other children”, and “have difficulty concen-
trating or paying attention”) showed a lower items internal 
consistency. However, the overall internal consistency was 
acceptable for all the domains.
In the external validity evaluation, the Spearman’s cor-
relations of the PF and HRQoL scores with JIA core set 
parameters ranged from weak to strong.
The results obtained for the parent version of the JAMAR 
are very similar to those obtained for the child version, 
which suggests that children are equally reliable proxy 
reporters of their disease and health status as their parents. 
The JAMAR is aimed to evaluate the side effects of medi-
cations and school attendance, which are other dimensions 
of daily life that were not previously considered by other 
HRQoL tools. This may provide useful information for inter-
vention and follow-up in health care.
In conclusion, the Omani Arabic version of the JAMAR 
was found to have satisfactory psychometric properties and 
it is, thus, a reliable and valid tool for the multidimensional 
assessment of children with JIA.
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